People: StemCells Inc (STEM.OQ)

STEM.OQ on NASDAQ Stock Exchange Capital Market

1.39USD
17 Sep 2014
Price Change (% chg)

$0.01 (+0.72%)
Prev Close
$1.38
Open
$1.35
Day's High
$1.41
Day's Low
$1.35
Volume
70,841
Avg. Vol
308,118
52-wk High
$2.42
52-wk Low
$1.16

Search Stocks

Summary

Name Age Since Current Position

John Schwartz

79 1998 Independent Chairman of the Board

Martin McGlynn

67 2001 President, Chief Executive Officer, Director

Gregory Schiffman

56 2014 Chief Financial Officer, Executive Vice President - Finance

Ann Tsukamoto

61 2013 Executive Vice President - Scientific and Strategic Alliances

Kenneth Stratton

45 2007 General Counsel

Alan Trounson

2014 Director

Irving Weissman

74 1997 Director

Eric Bjerkholt

54 2004 Independent Director

R. Scott Greer

55 2010 Independent Director

Ricardo Levy

69 2001 Independent Director

Biographies

Name Description

John Schwartz

Dr. John J. Schwartz, Ph.D., is Independent Chairman of the Board of StemCells, Inc. Dr. Schwartz has over 40 years of business and legal experience, including several years spent in the 1990s as President and Chief Executive Officer of Systemix, Inc., a cell-based therapeutics company which was acquired by Novartis in 1997. Before joining Systemix as its Senior Vice President and General Counsel in 1993, Dr. Schwartz served as the Vice President and General Counsel of Stanford University. He currently runs a registered investment advisor firm called Quantum Strategies Management Company.

Martin McGlynn

Mr. Martin M. McGlynn is President, Chief Executive Officer, Director of StemCells, Inc. He has held management positions of increasing responsibility in several countries for more than 30 years. Prior to joining our company, Mr. McGlynn was President and Chief Executive Officer of Pharmadigm, Inc., a privately held company in the fields of inflammation and genetic immunization. Prior to this, he was President and General Manager of Abbott Canada Ltd. and President of Anaquest, Inc., a company focused on anesthesia and acute care pharmaceuticals.

Gregory Schiffman

Mr. Gregory T. Schiffman has been appointed as Chief Financial Officer, Executive Vice President - Finance of StemCells, Inc., effective January 1, 2014. Mr. Schiffman is a seasoned executive in the healthcare industry, with over fifteen years of experience leading the financial operations and strategy of global publicly-traded companies such as Affymetrix and Applied Biosystems. Most recently, Mr. Schiffman was Executive Vice President and CFO of Dendreon Corporation since 2007, where he had primary responsibility for capital raising, financial reporting and controls, information technology, and investor relations. In April 2010, Dendreon secured marketing authorization from the U.S. Food and Drug Administration (FDA) for Provenge®, the world's first cell–based autologous immunotherapy for prostate cancer, followed by European Commission authorization in September 2013. Before entering the healthcare field, Mr. Schiffman held roles of increasing responsibility within Hewlett Packard, where he served as controller of its European P.C. manufacturing and distribution operations in Grenoble, France, and as manufacturing manager and controller of its Netmetrix Division. Mr. Schiffman holds a bachelor's degree in accounting from De Paul University and an MBA from the Kellogg Graduate School of Management at Northwestern University.

Ann Tsukamoto

Dr. Ann Tsukamoto, Ph.D., is Executive Vice President - Scientific and Strategic Alliances of StemCells, Inc. She was appointed Vice President, Scientific Operations in June 1998; Vice President, Research and Development in February 2002; Chief Operating Officer in November 2006; and Executive Vice President, Research and Development, in October 2008. In June 2013, Dr. Tsukamoto was appointed Executive Vice President, Scientific and Strategic Alliances, with responsibility for developing the Company’s alliances with research institutions, corporations, government agencies, and disease foundations. Dr. Tsukamoto is married to one of our outside directors.

Kenneth Stratton

Mr. Kenneth Stratton, J.D., is General Counsel of StemCells, Inc. In March 2008, he assumed responsibility for the Human Resources function. Prior to joining StemCells, Mr. Stratton served as Deputy General Counsel for Threshold Pharmaceuticals and as Senior Legal Counsel for Medtronic, Inc.’s Vascular business unit.

Alan Trounson

Dr. Alan O. Trounson, Ph.D. is Director of StemCells, Inc. Dr. Trounson has been the recipient of over 30 awards and distinctions for his scientific work, including pioneering work in the fields of in-vitro fertilization and stem cells. As part of his academic research, Dr. Trounson pioneered a new stem cell biology approach for the treatment of a broad range of diseases and injuries, which was awarded the first ever Australian Center of Excellence in Biotechnology grant worth $110 million dollars. Dr. Trounson's previous academic positions include Scientific Director of Monash IVF Pty Ltd., Personal Chair in Stem Cell Science and Director of the Monash Immunology and Stem Cell Laboratories, Deputy Director/Director of the Monash Institute of Reproduction and Development, Director of the Centre of Early Human Development, Facility of Medicine, and Personal Chair of Obstetrics and Gynaecology-Pediatrics at Monash University in Melbourne, Australia. He has founded a number of companies including Infertility Medical Center Pty Ltd./Monash IVF Pty Ltd., IVF Australia Corp/IntegraMed Corp (US), Sydney IVF Pty Ltd./Genea Pty Ltd., Maccine Pte Ltd and the Australian Stem Cell Center Ltd. He established two foundations, the Low Cost IVF Foundation for the treatment of infertile women in Africa and for the treatment of patients with HIV, to avoid vertical transmission to children and the Friends of Low Cost IVF (US). He is returning to Melbourne to continue to support international biotechnology in regenerative medicine.

Irving Weissman

Dr. Irving L. Weissman, M.D., is Director of StemCells, Inc. Dr. Weissman was elected to the Board of Directors in September 1997. He is the Virginia and Daniel K. Ludwig Professor of Cancer Research, Professor of Pathology and Professor of Developmental Biology at Stanford University.

Eric Bjerkholt

Mr. Eric H. Bjerkholt is an Independent Director of StemCells, Inc. Mr. Bjerkholt is a financial expert and currently serves as the Executive Vice President and Chief Financial Officer of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company. His business experience spans more than 20 years, during which time he founded a nutraceutical company and worked as an investment banker. Mr. Bjerkholt currently serves on the board of directors of Round Table Pizza.

R. Scott Greer

Mr. R. Scott Greer is an Independent Director of StemCells, Inc. Mr. Greer was appointed to the Board of Directors in June 2010. He is currently a principal and managing director of Numenor Ventures LLC, which he founded in 2002 to provide funding and strategic advisory services to early stage enterprises. Mr. Greer currently serves as Chairman of Ablexis, a development stage biotechnology company, and he is also on the board of Nektar Therapeutics.

Ricardo Levy

Dr. Ricardo B. Levy, Ph.D., is an Independent Director of StemCells, Inc. Dr. Levy was elected to the Board of Directors in September 2001. He currently serves as a director on the board of Accelrys, Inc., a public company focused on molecular modeling and simulation software for both life and materials science research.

Basic Compensation

Options Compensation

Search Stocks